This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Most U.S. states do not currently cover highly sought after weight-loss drugs from Novo Nordisk and Eli Lilly in their Medicaid health programs for low income people, citing…
Reuters Health Information